2 Cash-Producing Stocks with Impressive Fundamentals and 1 Facing Challenges

Barchart·06/03/2026 04:54:20

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here are two cash-producing companies that excel at turning cash into shareholder value and one that may struggle to keep up.

One Stock to Sell:

Monro (MNRO)

Trailing 12-Month Free Cash Flow Margin: 3.4%

Started as a single location in Rochester, New York, Monro (NASDAQ:MNRO) provides common auto services such as brake repairs, tire replacements, and oil changes.

Why Are We Out on MNRO?

1. Recent store closures and weak same-store sales point to soft demand and an operational restructuring
2. Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand
3. Performance over the past three years shows each sale was less profitable as its earnings per share dropped by 31.9% annually, worse than its revenue

Monro is trading at $15.78 per share, or 41.6x forward P/E. Check out our free in-depth research report to learn more about why MNRO doesn’t pass our bar.

Two Stocks to Buy:

Clover Health (CLOV)

Trailing 12-Month Free Cash Flow Margin: 2.5%

Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ:CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care.

Why Do We Love CLOV?

1. Annual revenue growth of 31.2% over the last two years was superb and indicates its market share increased during this cycle
2. Adjusted operating margin improvement of 25.6 percentage points over the last five years demonstrates its ability to scale efficiently
3. Free cash flow profile has moved into positive territory over the last five years, indicating the company has achieved financial self-sustainability

Clover Health’s stock price of $3.71 implies a valuation ratio of 43.6x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.

Oscar Health (OSCR)

Trailing 12-Month Free Cash Flow Margin: 21%

Founded in 2012 to simplify the notoriously complex American healthcare system, Oscar Health (NYSE:OSCR) is a technology-focused health insurance company that offers individual and small group health plans through its cloud-native platform.

Why Will OSCR Outperform?

1. Impressive 42.6% annual revenue growth over the last two years indicates it’s winning market share this cycle
2. Earnings growth has massively outpaced its peers over the last four years as its EPS has compounded at 31.5% annually
3. Free cash flow margin expanded by 19.9 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends

At $21.02 per share, Oscar Health trades at 19.7x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.